Clinical trials: Solid Malignant Tumor
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy
RATIONALE: Gabapentin may prevent or reduce delayed nausea and vomiting caused by chemotherapy. It is not yet known whether gabapentin is more effective than a placebo in preventing nausea and vomiting.
- Trial name
- NCT00880191
- Testing
- dexamethasone, gabapentin
- Where
- 247 sites in United States
- Volunteers
- 430 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Solid Tumor, Adult
K-BASKET, TAS-117, PI3K/AKT Gene Aberration
The phosphatidylinositol 3-kinase (PI3K)-v-akt murine thymoma viral oncogene homolog (AKT)-mammalian target of rapamycin (mTOR) signaling pathway is one of the most frequently aberrantly regulated pathways in human tumors.
- Trial name
- NCT03017521
- Testing
- TAS-117
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- Yonsei University
Soft-tissue Sarcomas
Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide
Assessment of the efficacy and safety of trabectedin and metronomic cyclophosphamide (CP) in patients with advanced pretreated soft-tissue sarcomas, once the Maximum Tolerated Dose (MTD) have been determined (phase I trial).
- Trial name
- TARMIC (NCT02805725)
- Testing
- Phase 1: Trabectedin, Phase 2: Trabectedin, Phase 1: Cyclophosphamide
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut Bergonié
Solid Tumor, Hematologic Malignancy
Implementation of an Oral Chemotherapy Adherence Intervention
The goal of this study is to evaluate the effectiveness and usability of a newly developed oral anticancer agent adherence program implemented across 6 cancer clinics (two academic, two urban, and two rural).
- Trial name
- NCT06989489
- Testing
- Multilevel Adherence Intervention
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Localized Malignant Solid Neoplasm, Anal Cancer
Distance-Based Exercise to Preserve Function and Prevent Disability
This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home.
- Conditions
- Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer
- Trial name
- DEFEND (NCT07059884)
- Testing
- Exercise intervention, Telemedicine, Aerobic Exercise Intervention
- Where
- 30 sites in United States
- Volunteers
- 104 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Solid Tumors
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
The primary objectives of this trial are to: Characterize the safety and tolerability of TEV-56278 Determine the Recommended Phase 2 Dose (RP2D) Evaluate antitumor activity of TEV-56278 (Part 2 only) Determine the safety and…
- Trial name
- NCT06480552
- Testing
- TEV-56278, Pembrolizumab
- Where
- 12 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Solid Tumor, Advanced Solid Tumor
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
A national, prospective, multi-center, open-label, multi-cohort study comprised of a framework to screen patients for actionable targets and evaluation of molecular profiling guided therapy recommended by MTB based on genomic…
- Conditions
- Solid Tumor, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- KOSMOSII (NCT05525858)
- Testing
- Alectinib, Atezolizumab, Erlotinib
- Where
- 32 sites in South Korea
- Volunteers
- 1,000 people
- Sponsor
- Seoul National University Bundang Hospital
Part A and B: Advanced Solid Malignancies, Part C: Malignant Mesothelioma
Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, PK and Preliminary Anti-tumor Activity when given as a monotherapy of Tremelimumab or Tremelimumab in combination with MEDI4736 in Japanese Patients…
- Trial name
- NCT02141347
- Testing
- Tremelimumab, MEDI4736
- Where
- 11 sites in Japan
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Solid Tumor, Hematological Malignancies
The Good Patient Study
Adolescents with cancer weigh multiple influences in medical decision-making, including their own best interest, the perceived wishes of family members, and the interpreted preferences of the health care team.
- Conditions
- Solid Tumor, Hematological Malignancies, Brain Tumor
- Trial name
- NCT02199548
- Testing
- Interview
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- St. Jude Children's Research Hospital
Advanced Solid Tumor, Advanced Colorectal Carcinoma
Combining Epigenetic And Immune Therapy to Beat Cancer.
Umbrella study structure to independently and simultaneously assess the effects of the association of durvalumab and tazemetostat in multiple solid tumors.
- Conditions
- Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Pancreatic Adenocarcinoma
- Trial name
- CAIRE (NCT04705818)
- Testing
- Durvalumab, Tazemetostat
- Where
- 3 sites in France
- Volunteers
- 164 people
- Sponsor
- Institut Bergonié
Tumor, Solid, Children
Standardized Nutritional Management of Pediatric Patients With Solid Tumors
The purpose of this study is to establish a standardized nutrition intervention procedure for children with solid tumors, and to explore the effectiveness and clinical applicability of standardized nutrition management and short…
- Conditions
- Tumor, Solid, Children, Nutritional Intervention
- Trial name
- NCT06730204
- Testing
- Standardized nutritional management, Standardized nutritional management + short peptide ONS
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Children's Hospital of Fudan University
Infection, Neutropenia
Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy
RATIONALE: Antibiotics, such as daptomycin and vancomycin, may be effective in treating bacteria in the blood. It is not yet known whether daptomycin is more effective than vancomycin in treating bacteria in the blood in patients…
- Conditions
- Infection, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00296049
- Testing
- daptomycin, vancomycin
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Solid Tumor, Non-Hodgkin Lymphoma
Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
The purpose of this study is to assess the safety and tolerability of gentulizumab, an anti-CD47 Monoclonal Antibody, in participants with solid tumors and non-Hodgkin lymphoma.
- Trial name
- NCT05221385
- Testing
- Gentulizumab
- Where
- 2 sites in China
- Volunteers
- 58 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Lymphoma, Solid Tumor (Excluding CNS)
Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
This is a phase 1, open-label, dose escalation study to evaluate the safety, pharmacokinetics, and antitumor activity of pixantrone in pediatric patients with relapsed or refractory solid tumors (excluding those with CNS tumors)…
- Trial name
- NCT02800889
- Testing
- Pixantrone
- Where
- United States
- Sponsor
- CTI BioPharma
Tumors, Medical Oncology
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
A study examining the safety of AGS-22M6E or ASG-22CE administered as monotherapy therapy in subjects with malignant solid tumors that express Nectin-4.
- Conditions
- Tumors, Medical Oncology, Neoplasms
- Trial name
- NCT01409135
- Testing
- AGS-22M6E, ASG-22CE
- Where
- 9 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Astellas Pharma Inc
Cancer, Neoplasms
Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain
Background: Cancer pain can have a very negative effect on people s daily lives. Researchers want to use machine learning to detect facial expressions and voice signals.
- Conditions
- Cancer, Neoplasms, Solid Tumors
- Trial name
- NCT04442425
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Pancreatic Cancer
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.
- Conditions
- Gastric Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT06134960
- Testing
- KD-496
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Peking University
Solid Tumor
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies…
- Trial name
- NCT05373147
- Testing
- αPD1-MSLN-CAR T cells
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Mengchao Cancer Hospital
Tumor, Solid
A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors
The goal of this clinical trial is to learn if tumor neoantigen-specific T cells can treat patients with advanced solid tumors. The main questions it aims to answer are: Evaluate the safety of intravenous infusion of tumor…
- Trial name
- Neoantigen-T (NCT06431529)
- Testing
- tumor neoantigen specific T cell
- Where
- China
- Volunteers
- 6 people
- Sponsor
- JIANG LONGWEI
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ROS1 translocation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439253
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.